7 June 2022

What's new in immunotherapies 2022

Organised by:

SCI’s Fine Chemicals Group

SCI, London, UK

Register your interest

Registration Closed

This event is no longer available for registration.


Immunotherapy is a hot-topic field of research that has generated significant scientific interest and fuelled industrial innovation.

It has been demonstrated that small, drug-like molecules can be highly effective modulators of immune response pathways and that their molecular properties can be fine-tuned to enable excellent cell permeability and bioavailability. This makes them ideal for use in the treatment of chronic conditions such as autoimmune and inflammation-related diseases. Excitingly, this approach also offers the possibility to treat cancer by harnessing the body’s own immune system to fight tumours.

This meeting will offer a broad introduction to those new to the topic and showcase recent innovations by academic and industrial scientists in this exciting and rapidly expanding field.

Call for posters

An abstract of maximum one A4 page or 300 words indicating title and authors should be sent to conferences@soci.org by Friday 29 April with the subject line “What's New in Immunotherapies - poster abstract submission". Please use the template attached here.


The event is targeted at research students, researchers, academic and industrial scientists engaged in all aspects of research into small molecule immunotherapy, and those interested in broadening their knowledge in this growing field.

This event is being held back to back with "Targeting protein degradation 3 – from discovery to the clinic".

7 June 2021

Registration and Refreshments
Welcome and introduction
In vitro assays for immunotherapy drug discovery programs; overview and emerging areas
Dr Justyna Rzepecka, Concept Life Sciences
Prof. Edward Tate; Imperial College Myricx Pharma Ltd and Crick Institute
Optimisation of Mer/Axl kinase inhibitors for immuno-oncology
Dr William McCoull, AZ
Lunch and poster session
The discovery of BD2 selective BET inhibitors
Dr Emmanuel Demont, GSK
First-in-class inhibitors of ERAP1 alter the immunopeptidome of cancer, driving a differentiated T cell response leading to tumour growth inhibition
Andrew Leishman, Grey Wolf therapeutics
Discovery and Development of Novel Small Molecule Inhibitors of IL-17
Dr Anne Foley, UCB
Enabling Natural Killer Cell Immunotherapy of Cancer with Small Molecules
Prof. Matt Fuchter Imperial College and NK:IO Ltd
Panel Discussion
Wine Reception


Before early bird - ends 26 April 2022
SCI Member - £80
Non-member - £120
Student member - £35
After early bird
SCI Member - £130
Non-member - £170
Student member - £50


There is a 10 percent reduction on the registration fee if you register for the Targeting protein degradation 3 – from discovery to the clinic event in addition to this meeting for SCI members and non-members.

Once you have registered for this event, please email conferences@soci.org for a voucher code.

All registrations will automatically receive a confirmation within 24 hours of registering for the event. Should you not receive written confirmation of your booking, please email conferences@soci.org.

Become an SCI Member and save on this and future events

See Membership Options

Sign up as an Event Member to join this event. SCI Full or Student Members receive discounts on event registrations

Booking Process/Deadlines

Booking terms and conditions

CPD Information

SCI Members attending this meeting are able to claim CPD points.





For further information and prices, please email conferences@soci.org

Organising Committee
  • Tilly Bingham, SCI/ Concept Life Sciences
  • Nicola Chessum, SCI
  • Jayshree Mistry, SCI/ Modgraph Consultants


Conference Team

Tel: +44 (0)20 7598 1561

Email: conferences@soci.org